JPMorgan Chase & Co. Begins Coverage on Omada Health (NASDAQ:OMDA)

JPMorgan Chase & Co. initiated coverage on shares of Omada Health (NASDAQ:OMDA - Free Report) in a report published on Tuesday, Marketbeat reports. The brokerage issued an overweight rating and a $19.00 price target on the stock.

Several other research firms have also issued reports on OMDA. The Goldman Sachs Group initiated coverage on shares of Omada Health in a research report on Tuesday. They issued a "buy" rating and a $29.00 price target on the stock. Barclays started coverage on Omada Health in a report on Tuesday. They issued an "overweight" rating and a $21.00 target price on the stock. Needham & Company LLC assumed coverage on Omada Health in a report on Tuesday. They set a "buy" rating and a $23.00 target price for the company. Canaccord Genuity Group started coverage on Omada Health in a research report on Tuesday. They issued a "buy" rating and a $27.00 price target for the company. Finally, Wall Street Zen upgraded Omada Health to a "hold" rating in a report on Monday, June 16th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $23.57.

Omada Health Stock Up 2.9%

Shares of OMDA traded up $0.53 during mid-day trading on Tuesday, hitting $18.63. The company's stock had a trading volume of 344,526 shares, compared to its average volume of 1,585,299. Omada Health has a fifty-two week low of $14.14 and a fifty-two week high of $28.40.

Omada Health Company Profile

Omada's mission is to bend the curve. Our hope is that, one day, tomorrow's epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms.